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	 	 	 	 ABSTRACT	OF	THESIS
INTERLEUKIN-10	RECEPTOR	DYSFUNCTION	IN	PERITONEAL	
MACROPHAGES	BY	TOLL-LIKE	RECEPTOR	LIGANDS
Interleukin-10 (IL-10) is a pleiotropic cytokine which limits inflammatory 
responses	by	balancing	the	host’s	immune	response	against	infection.	
Mammalian	Toll-like	receptors	(TLRs)	are	pattern	recognition	receptors	that	
recognize specific molecular pattens on microbial pathogens and activate 
intracellular signaling via the transcription factors NF-κB and IRF-3. In this 
study we evaluate the contribution of the TLR ligands Poly I:C, Pam
3
CSK4, 
LPS and LTA to IL-10 receptor dysfunction in murine peritoneal macrophages 
(PM). We examine how these ligands are able to alter IL-10 mediated STAT3 
phosphorylation and CCR5 gene expression in PM. The ability of Poly I:C and 
Pam
3
CSK4 to alter the immunosuppressive activity of IL-10 in C2-ceramide 
stimulated PM is also examined. The results of our study indicate a delayed 
inhibition of IL-10 mediated activation of STAT3 by LPS, LTA, Poly I:C and 
Pam
3
CSK4. The CCR5 gene expression experiments demonstrate that LPS was 
able to down-regulate IL-10 induced CCR5 mRNA expression in PM.
KEYWORDS: Interleukin-10, STAT3, Toll-like receptors, Poly I:C, Pam
3
CSK4.
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Introduction
Interleukin-10 (IL-10) is a multifunctional cytokine which has diverse effects on 
various types of hematopoietic cells, including B and T lymphocytes, natural 
killer cells (NK) cells, mast cells, and eosinophils (1,2). IL-10 regulates growth 
and differentiation of B cells, NK cells, cytotoxic and helper T cells, mast cells, 
granulocytes, dendritic cells, keratinocytes, and endothelial cells (1). IL-10 is 
also crucial in the differentiation and function of T regulatory cells, which play 
a prominent role in the control of immune responses and tolerance in vivo (1). 
IL-10 can be produced by both CD4+ and CD8+ T cells, B cells, monocytes, 
macrophages, and dendritic cells (2). IL-10 can inhibit production of cytokines 
such as IL-2 and interferon-γ	(IFN-γ)	by	Th1	type	T	cells	(1).	This	inhibitory	effect	
of IL-10 is mediated indirectly via effects on antigen-presenting cells (APCs), 
including monocytes, macrophages and dendritic cells (2). IL-10 can inhibit a 
variety of macrophage/monocyte functions, including IL-12 and NO production, 
and expression of class II MHC and costimulatory molecules like CD80/CD86 (2). 
IL-10 can also inhibit production of IL-1α, IL-1β, IL-6, IL-12, IL-18, GM-CSF, G-
CSF, M-CSF, TNF, LIF, and PAF by activated macrophages (3,4,5,6). 
The principal in vivo function of IL-10 appears to limit and ultimately terminate 
inflammatory responses (1). IL-1 and TNF synergistically activate inflammatory 
pathways and processes, and induce chemokines, prostaglandins, and PAF, 
which amplify the inflammatory responses (1). IL-10 inhibits both CC and CXC 
chemokines, which are involved in recruitment of monocytes, dendritic cells, 
neutrophils, and T cells during inflammation (7,8,9). The anti-inflammatory 
activity of IL-10 is mediated in part by its inhibitory effects on both IL-1 and 
TNF production. IL-10 deficient mice demonstrate exaggerated inflammatory 
responses like inflammatory bowel disease (IBD), which clearly demonstrates the 
importance of IL-10’s anti-inflammatory function (10,11).
IL-10 plays a crucial role in striking a balance between immune-mediated 
pathology and protection in the tissues of an infected host, which tries to provide 
a sufficiently intense immune response against the infection, while minimizing 
nonspecific tissue injury. In vitro methods have been used to study some 
aspects of IL-10 biology by evaluating the influence of IL-10 on the response 
of individual cell types to microorganisms or microbial products (1). The 
shortcomings of these studies are that host-pathogen interactions are complex, 
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and vary according to the life-cycle of the pathogen and progress of the 
host’s immune response (1). Animal models, principally mouse, of infectious 
disease have been used to evaluate the overall role of IL-10 in the recovery 
from infection. Aspects of both innate and adaptive immune responses are 
enhanced by experimental depletion of IL-10 in vivo, while the same responses 
are impaired by experimental elevation of IL-10 in vivo. Elevated IL-10 severely 
compromises	innate	immune	responses	to	Listeria	in	scid mice (12), while there 
are enhanced immune responses to Listeria in IL-10 -/- mice (13). Similarly, 
there is rapid control of Listeria within the first few days of infection in anti-IL-10 
treated mice (14).
IL-10 and IL-10 Receptor Structure
The bioactive form of of IL-10 is a homodimer consisting two 18 kDa subunits 
which are noncovalently associated. In monocytes, the expression of the IL-10 
gene can be induced by Gram-positive and Gram-negative bacteria, purified 
endotoxin, bacterial exotoxins, and certain viruses (2). In lipopolysacchardide 
(LPS)-stimulated monocytes, the expression of the IL-10 gene is delayed 
relative to other cytokine genes, such as tumor-necrosis factor-α	(TNF-α) and 
IL-1 (3). In activated T cells, IL-10 gene expression also is delayed compared to 
other cytokine genes, such as IL-2 and IL-4 (15).  IL-10 receptors (IL-10R) are 
expressed by hematopoietic cells such as B cells, T cells, NK cells, monocytes, 
macrophages, and dendritic cells. Non-hematopoietic cells such as fibroblasts or 
endothelial cells do not express IL-10Rs (2). However, other non-hematopoietic 
cells have been shown to express functional IL-10Rs. The human IL-10R is 
species specific, while the murine IL-10R can bind both murine and human IL-10 
with comparable affinity. Functional IL-10R complexes are tetramers consisting 
of two IL-10R1 polypeptide chains and two IL-10R2 chains. The IL-10R1 chain 
is the ligand-binding chain of the IL-10R complex. Homodimeric IL-10 binds to 
the extracellular domains of the two adjoining IL-10 R1 molecules and activates 
phosphorylation of the receptor-associated Janus tyrosine kinases, JAK1 and 
Tyk2 (16,17). JAK1 associates with the IL-10R1 chain, while Tyk2 associates with 
the IL-10R2 chain. These kinases then phosphorylate specific tyrosine residues 
(Y446 and Y496) on the intracellular domain of the IL-10R1 chain (17,18,19). 
These phosphorylated Tyr residues and their flanking peptide sequences serve 
as docking sites for the latent transcription factor, STAT3 (Signal Transducer 
and Activator of Transcription 3). STAT3 binds to these docking sites by its SH2 
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domain, following which it is Tyr phosphorylated by the receptor associated 
JAKs. The phosphorylated STAT3 then homodimerizes and translocates to 
the nucleus where the dimer binds with high affinity to SBEs (STAT binding 
elements) in the promoters of various IL-10 responsive genes. One of these 
genes is SOCS3 (Suppressor of Cytokine signaling 3), which is known to inhibit 
JAK/STAT-dependent signaling, and acts to down-regulate IL-10R function. IL-10 
activates both STAT1α and STAT3 in most IL-10R positive cell types (16). Three 
distinct STAT complexes can be formed by activation of these STATs: STAT1 
homodimers, STAT3 homodimers, and STAT1:STAT3 heterodimers (18). This 
variation in the assembly of STAT complexes may induce distinct patterns of 
gene expression in different cell types (2).
Functional Effects of IL-10 Signaling
IL-10 inhibits expression of several LPS-inducible genes in monocytes, including 
the	cytokines	TNF-α, IL-1, IL-6, IL-8, IL-12, G-CSF, and GM-CSF. The expression 
of other LPS-inducible genes like cyclooxygenase-2 (Cox-2) is also inhibited by 
IL-10 (2). IL-10 inhibits expression of several IFN-γ inducible genes, including 
MHC class II molecules, B7, and IP-10 (25,26,24). In monocytes, IL-10 also 
activates expression of the genes   for CCR5, FcγR1, TIMP-1, TNF-R2, and 
SOCS-3 (20,21,22,23,24).
The critical role of IL-10 in regulating the immune response is seen in several 
chronic inflammatory diseases, where the function of IL-10 appears to be 
suppressed. It has been observed that IL-10 was not effective in suppressing 
cytokine production in monocytes or macrophages derived from patients with 
Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) (27, 28). 
In SLE there appears to be a defect in the IL-10-induced suppression of IL-6 
production. Mongan et al (27), examined recombinant human IL-10-mediated 
suppression of IL-6 production by monocytes and B cells from lupus patients, 
and compared the results with normal controls. IL-10 caused a concentration-
dependent suppression of IL-6 production in normal monocytes and B cells, 
which was not observed in the same cells from lupus patients. Another study 
has demonstrated that ligation of FcγRs by immune complexes inhibited IL-10 
induced activation of the Jak-STAT pathway in IFN-γ exposed, synovial fluid 
macrophages, obtained from RA patients (29).
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Regulation of IL-10 Receptor Function
One of the key regulators of the Jak-STAT signaling is a family of molecules 
known	as	suppressor	of	cytokine	siganaling	(SOCS).	Eight	members	of	the	
SOCS protein family have been identified, SOCS1 through SOCS7, and CIS 
(cytokine inducible SH2 domain protein) (30). SOCS3 inhibits Jak2 kinase 
activity by binding to the SH2 domain to regulate Jak-STAT signaling (31). This 
suggests that a similar interaction of SOCS3 with Jak1 of the IL-10R could 
also occur. IL-10 also induces SOCS1 expression which negatively regulates 
IL-10 function and IL-10R signaling (32). Preliminary studies in our lab have 
indicated that the Toll-like receptor (TLR) ligands, LPS, LTA and CpG ODN each 
induce the expression of both SOCS1 and SOCS3 mRNA within 1-3 hours in 
peritoneal macrophages (data not shown), which has also been observed in 
other studies (33,34). However, some groups have suggested that SOCS3 may 
not be involved in the regulation of IL-10R signaling (35,36). It is still unclear if 
SOCS1 or SOCS3, or other members of the SOCS family of proteins induced 
by TLR ligands, are involved in the inhibition of IL-10R function in macrophages. 
Hart et al have shown that prior exposure of macrophages to GM-CSF inhibited 
subsequent responsiveness of macrophages to IL-10 (37). Previous studies 
by	our	lab	suggest	that	pre-exposure	of	macrophages	to	TNF-α reduces their 
response to IL-10, which was not related to a change in receptor expression (38). 
The ability of IL-10 to inhibit LPS-induced production of IL-6 was significantly 
reduced in peritoneal macrophages pre-treated with TNF-α (38). We have also 
demonstrated that LPS, LTA, and CpG inhibited IL-10R signal transduction in 
alveolar and peritoneal macrophages and appeared to require the expression of 
the myeloid differentiation factor 88 (MyD88) adaptor protein without decreasing 
IL-10R expression. (39).  
Recognition of Microbes by the Innate Immune System
The innate immune system utilizes germ-line encoded receptors to recognize 
pathogens that express highly-conserved structures present in a large group of 
microorganisms. These microbial structures are known as pathogen-associated 
molecular patterns (PAMPs) and are produced by microbial pathogens, but not 
by their hosts. For example, LPS and LTA are cell wall components that are 
synthesized only by bacteria. Usually PAMPs are essential for the pathogenecity 
or survival of the microorganisms. Bacterial lipopolysaccharide (LPS), lipoteichoic 
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acid (LTA), bacterial DNA, double-stranded RNA, petidoglycan, mannans, 
and glucans are examples of some well known PAMPs. The receptors of the 
immune system that evolved to recognize PAMPs are collectively called pattern-
recognition receptors (PRRs). PAMPs are usually invariant structures that are 
present in an entire class of pathogen. For example, LPS is present in all gram-
negative bacteria and the specific PRR of the host recognizes virtually any gram-
negative bacterial infection (40).
PRRs are expressed on antigen-presenting cells including macrophages, 
dendritic cells and B cells. These cells are immediately activated once PRRs bind 
PAMPs, accounting for the rapid kinetics of the innate immune response. PRRs 
can be classified based on their structural domains into receptors having either 
leucine-rich repeats, calcium-dependent lectin, or scavenger-receptor protein. 
Functionally, PRRs can be divided into three classes: secreted, endocytic, 
and signaling (40). Secreted PRRs function as opsonins which bind to the 
microbial cell walls, thus initiating recognition by the complement system and 
phagocytes. An example of this class is mannan-binding lectin, which is also 
a member of the calcium-dependent lectin family (40). This receptor binds to 
microbial carbohydrates to initiate the lectin pathway of complement activation. 
Endocytic PRRs occur on the surface of phagocytes, which internalize and 
deliver the pathogen to lysosomes once these receptors recognize PAMPs on 
a	microbial	cell.	An	example	of	this	class	of	PRR	is	the	macrophage	mannose	
receptor, which also belongs to the calcium-dependent lectin family. It specifically 
recognizes carbohydrates with large number of terminal mannoses and mediates 
their phagocytosis by macrophages. Signaling receptors recognize PAMPs and 
activate signal-transduction pathways that induce the expression of genes of 
inflammatory cytokines and chemokines(40). Receptors of the Toll family belong 
to this class of PRRs and play a crutial role in Drosophila and Mammalian host 
defence. In mammals these receptors are called Toll-like Receptors (TLRs) 
and activate intracellular signaling via NF-kB or IRF-3, which results in the 
induction of a variety of effector genes (41). Since PAMPs are also expressed in 
commensal microorganisms, the term immune adjuvant may be more appropriate 
and TLRs could be defined as adjuvant receptors (42). In mammalian species 
there are at least eleven TLRs, each having a distinct function in innate immune 
recognition (42,43). Some common themes that are emerging are that TLR 
ligands tend to be conserved microbial products, which may be structurally 
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unrelated and some TLRs require accessory proteins to recognize their 	
specific ligands (43).
Based on their molecular characteristics TLR ligands can be divided into three 
categories: lipid, nucleic acid, and protein (42). The following are some examples 
of the above three categories of TLR ligands.
Lipid Ligands: Lipopolysaccharide (LPS) is a complex glycolipid which is an 
integral component of the Gram-negative bacterial cell wall. LPS is composed of 
a hydrophilic polysaccharide portion and a hydrophobic domain known as lipid A, 
which is responsible for its biological activity (44). TLR 4, the first characterized 
mammalian TLR, functions as the signal transducing receptor for LPS from 
Gram-negative bacteria (43,46). The recognition of LPS by TLR4 is complex and 
requires several accessory molecules. LPS first binds to a serum protein called 
LPS-binding protein (LBP), which then transfers LPS monomers to CD14. CD14 
can either secreted into serum or expressed as a glycophosphoinositol (GPI)-
linked protein on the surface of macrophages. Another component of the TLR4 
receptor complex is MD-2, which is a small protein lacking a transmembrane 
region that is expressed on the cell surface and associated with the ectodomain 
of TLR4 (43). The outer memabrane of Gram-positive bacteria have a thick layer 
of petidoglycan which also contains a variety of lipoproteins and lipopeptides. 
The    cytoplasmic membranes of mycoplasmas also have several lipopeptides. 
TLR2 recognizes several of these components by associating as homo- or 
heterodimers with other TLR2 relatives. For example, both TLR2 and TLR6 are 
required by macrophages to recognize peptidoglycan. Diacetylated mycoplasmal 
lipopeptides are recognized by TLR2:TLR6 heterodimers. TLR2 and TLR1 
cooperate in the recognition of bacterial lipopeptides (42). PAM
3
CSK4	is	a	
synthetic bacterial lipopeptide containing a triacetylated cysteinyl residue, which 
is recognized by the TLR2:TLR1 heterodimer (44).
Nucleic Acid Ligands: Bacterial DNA abundantly expresses unmethylated 
CpG motifs, while mammalian DNA rarely contains this motif. This structural 
difference is utilized by TLR9 in the host to alert the immune system of bacterial 
infections. TLR7 and TLR8 are highly homologous to each other and TLR9 
(42). Imidazoquinoline derivatives, imiquimod and resiquimod (R848), are 
TLR7 ligands which excert antiviral activity. Anticancer synthetic chemicals, 
including loxoribine (7-allyl-8-oxoguanosine), and bropirimine (2-amin-5-bromo-
6-phenyl4(3)pyrimidinone) and certain guanosine analogs are also TLR7 ligands. 
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Single-stranded RNAs derived from influenza virus or human immunodeficiency 
virus-1 and non-viral RNAs like poly-uridine, are also TLR7 ligands. Human TLR8 
recognizes R848 and certain ssRNAs. TLR7 and TLR9 recognize their ligands 
in a similar manner. TLR7 and TLR9 are both expressed in the endoplasmic 
reticulum and then move to the endosome, where they interact with their 
specific ligands. RNA virus infection leads to generation of double-stranded 
RNAs (dsRNAs), which are recognized by TLR3. Polyinosinic-polycytidylic acid 
(poly(I:C)), is a synthetic analogue of dsRNA which is effectively recognized 
by TLR3 (42).
Protein ligand: Flagellin, is a protein that forms bacterial flagella. The amino- and 
carboxy- termini of flagellin are extremely conserved and recognized by TLR5. 
TLR5 is expressed on the basolateral side, but not on the apical side 
of the intestinal epithelium. This polarized expression may account for 
discrimination between commensal and pathogenic bacteria, since only the latter 
cross the epithelial barriers (42, 43).
TLR Signaling Pathway
An intracytoplasmic domain of all TLRs is similar to each other and to the other 
IL-1R family members. This highly conserved domain is called the Toll/IL-1R 
homologous (TIR) domain. MyD88 is a cytoplasmic adaptor which also contains 
of a TIR domain and can interact with both TLRs and IL-1Rs, via interaction 
between the respective TIR domains (42). When activated, MyD88 recruits a 
death domain-containing serine/threonine kinase, the IL-1R-associated kinase 
(IRAK). IRAK is subsequently activated by phosphorylation and then associates 
with tumor necrosis factor-associated factor 6 (TRAF6), leading to NF-κB	
activation. Under normal conditions, IκB sequesters NF-κB in the cytoplasm and 
regulates its activity. Phosphorylation of IκB on serine residues by the IκB	kinase	
(IKK) complex leads to the dissociation and nuclear translocation of NF-κB (45). 
LPS is also able to activate NF-κB with delayed kinetics in MyD88-deficient 
macrophages, indicating that there is also a MyD88-independent component 
in the LPS signaling pathway (45,46). It seems that this alternate pathway 
is responsible for the LPS-induced maturation of dendritic cells (45). LPS 
stimulation leads to the activation of the transcription factor IFN-Regulatory 
Factor-3 (IRF-3), which then induces IFN-β. Viral-derived dsRNA is also a potent 
activator of IRF-3 through the MyD88-independent pathway, which then also 
7
initiates	IFN-β induction. It seems that the IKKs Tank-binding kinase (TBK-1) and 
IKKε/IKKι regulate activation of IRF-3 by phosphorylation in response to TLR3 
activation. However, it is unclear if these IKKs are involved in TLR4-mediated 
IRF-3 activation (46).
Studies in this dissertation tested the hypothesis that the IRF-3 pathway 
contributes to IL-10R dysfunction in peritoneal macrophages. Peritoneal 
macrophages were examined for altered responsiveness to IL-10 following 
exposure to the TLR ligands LPS (E. coli), Poly(I:C), and Pam3CSK4. LPS is 
known to activate both the IRF-3 pathway and the MyD88 pathway, while Poly 
(I:C) activates the IRF-3 pathway only (46), and Pam3CSK4 activates only the 
MyD88 pathway (44). The results of this study indicate a delayed inhibition of 
IL-10 mediated activation of STAT3 by TLR ligands LPS, LTA, Poly (I:C), and 
Pam
3
CSK4. CCR5 gene expression experiments demonstrate that LPS was able 
to down-regulate IL-10 induced CCR5 mRNA expression in PM. Also, Poly (I:C) 
and Pam
3
CSK4 seem to reduce IL-10 mediated suppression of TNF-α production 
by C2-ceramide.
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Materials and Methods
Mice and Reagents
Normal C57BL/6 (6-8 weeks old) female mice were purchased from Jackson 
Laboratories. Mice were allowed to acclimate for 1-2 weeks in microisolator 
cages and were provided with sterile water and food ad libitum and maintained 
by	the	Department	of	Laboratory	Animal	Resources.	E. coli 0111:B4 
lipopolysaccharide (LPS), Streptococcus aureus lipoteichoic acid (LTA), and C2-
ceramide (N-Acetyl-D-sphingosine), were purchased from Sigma-Aldrich (St. 
Louis, MO). Poly (I:C) was obtained as a gift from Dr. Maria Bruno in 	
Dr.	Charlotte	Kaetzel’s	laboratory.	Pam
3
CSK4 was purchased from InvivoGen 
(San Diego, CA). Alexa Fluor 680 goat anti-rabbit IgG (H+L) Ab was purchased 
from Molecular Probes (Eugene, OR), and IR Dye 800CW goat anti-mouse IgG 
(H+L) Ab was purchased from Rockland (Gilbertsville, PA). Anti-phospho-STAT3 
Ab was purchased from Cell Signaling Technology (Beverly, MA), and anti-
STAT3 Ab was obtained from BD Biosciences (Lexington, KY). Odyssey blocking 
buffer was obtained from LI-COR Biosciences (Lincoln, NE). Recombinant 
murine IL-10 (rm IL-10) was purchased from Peprotech (Rocky Hill, NJ). 
Peritoneal macrophages (PM) were obtained by lavage with PBS from normal, 
unmanipulated mice for all studies. 
Western Blot Analysis
PM from normal C57BL/6 (6-8 weeks old) female mice were seeded in 6-well 
plates	at	1x106 cells per well in RPMI 1640 medium containing 0.2% fetal calf 
serum plus penicillin and streptomycin (complete medium). After overnight 
incubation, adherent cells were washed twice in complete medium before adding 
2ml of complete medium to each well. Cells were then stimulated with LPS, LTA, 
Poly (I:C), Pam3CSK4, or medium alone as described, followed by 5ng/ml rmIL-
10 for 30 minutes.  At the end of the experiment the medium was aspirated and 1 
ml of cold PBS was added to each well to terminate the reaction. The cells were 
then scraped off with a cell scraper and the suspension was then transferred 
to Eppendorf tubes. The samples were then centrifuged at 3000 rpm for 15 
minutes after which the sample supernatants were aspirated. The cell pellets 
were then dissolved in 40 µl of cell lysis buffer (0.5% Triton X-100, 300mM NaCl, 
0.25mM EDTA, 50mM Tris, pH=7.5) in the presence of sodium orthovanadate 
and protease inhibitor mixture set III (Calbiochem, San Diego, CA). The samples 
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were then frozen at -20oC overnight, after which the samples were thawed and 
sonicated for 5 seconds. Samples were then centrifuged at 7000 rpm for 10 
minutes after which the sample supernatants were transferred to separate tubes. 
Protein determination was performed on these supernatants using bicinchoninic 
acid reagents (Bio-Rad, Hercules, CA). Up to 5 µg	of	whole	cell	lysate	protein	
was resolved on SDS 8% polyacrylamide gels and transferred to nitrocellulose 
membranes (Bio-Rad). Blots were then blocked for I hour in Odyssey blocking 
buffer without Tween-20. Phospho-STAT3 and STAT3 were detected by 
coincubating membranes overnight at 4 degrees C with anti-phosphoSTAT3 
polyclonal Ab (1:1000 dilution) and anti-STAT3 Ab (1:1000 dilution) in Odyssey 
blocking buffer containing 0.1% Tween-20.  Membranes were then washed thrice 
(15 minutes each wash) in PBS with 0.1% Tween-20. Membranes were then 
incubated for 1 hour at room temperature with Alexa Fluor 680 goat anti-rabbit 
IgG (H+L) Ab and IRDye 800CW goat anti-mouse IgG (H+L) Ab (both at 1:10,000 
dilution) in Odyssey blocking buffer containing 0.1% Tween-20. The membranes 
were washed four times (15 minutes each wash) in PBS with 0.1% Tween-20. 
The blots were analyzed on the LI-COR Odyssey imaging system. 
RT-PCR
Peritoneal macrophages (PM) from normal C57BL/6 (6-8 weeks old) female 
mice were seeded in 6-well plates at 1x106	cells	per	well	in	complete	RPMI	
medium. After overnight incubation, adherent cells were washed twice in the 
same medium before adding 2ml of complete medium to each well. Adherent 
cells were stimulated with rmIL-10 (5ng/ml) for 26 hours at 37oC. LPS, Poly I:
C, and PAM
3
CSK4 were added 2 hours after the IL-10 treatment. Total RNA was 
extracted using TRIzol reagent following the manufacturer’s protocol. 
Total RNA was reverse-transcribed using Superscript II reverse transcriptase 
(Invitrogen, Carlsbad, CA) for 45 min at 42oC. cDNA was used as a template 
for	PCR	using	Taq DNA polymerase (Invitorgen). CCR1 and CCR5 PCRs were 
performed at 30-35 cycles. As a loading control, β-actin PCR was performed 
at 30 cycles. PCR products were electrophoresed in 1.2% agarose-containing 
ethidium bromide. 
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TNF-α induction by C2-ceramide
PM were plated in 24 well plates at 0.5x106 cells per well and allowed to adhere 
overnight in 0.2% FCS RPMI medium. After washing off the non-adherent cells, 
the cultures were incubate in the same medium and treated with or without 
Poly I:C (20 µg/ml) or Pam3CSK4 (200 ng/ml) for 24 hours. Cultures were then 
washed again to remove the ligand and incubated in serum free RPMI 1640 in 
the absence or presence of IL-10 (5ng/ml) for 2 hours. 1 µM of C2-ceramide 
was then added to some wells. Cultures were further incubated for 4 hours. 
Medium was collected and stored at -20oC	until	TNF-α	protein	content	was	
evaluated using an OptEIA TNF-α ELISA kit by BD PharMingen, following the 
manufacturer’s	protocol.
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Results
Preliminary studies demonstrated that exposure of PM to recombinant murine 
IL-10 induced a time dependent phosphorylation of STAT3, which was maximal 
at 30 minutes after exposure and began to decay 60 minutes after exposure 
to IL-10. Consequently, exposure to IL-10 for 30 minutes was chosen for all 
experiments involving immunoblotting. Previous studies in the laboratory have 
demonstrated that pre-exposure of alveolar macrophages to LPS and LTA 
transiently reduced IL-10 mediated STAT3 phosphorylation. LPS was observed 
to inhibit IL-10 mediated STAT3 phosphorylation from 6-24 hours pretreatment, 
while LTA showed moderate inhibitory effects at 12 hour pretreatment (39).
The goal of these studies was to evaluate the ability of other TLRs ligands to 
inhibit IL-10 signal transduction. We chose to evaluate the ligand for TLR3 (Poly 
I:C), since it signals via IRF-3, and demonstrates a delayed activation of NF-
κB independent of MyD88 (42,54). The TLR4 ligand LPS was also evaluated 
since it has the unique ability to activate NF-κB using both MyD88-dependent 
and independent pathways, and also activate IRF-3 in a MyD88 independent 
manner (42). We also re-evaluated IL-10R dysfunction through TLR2 by using 
the synthetic ligand Pam
3
CSK4, since LTA preparations are often contaminated 
by other microbial components. In addition, Pam
3
CSK4	signals	through	a	
TLR2/TLR1 heterodimer (44), whereas LTA binds only to TLR2 and only signals 
through the MyD88 adaptor protein (53).
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Inhibition of IL-10 Signaling by LPS
Previous studies by Fernandez et al (39) showed that prior incubation of 	
normal alveolar macrophages with LPS for at least 9 hours caused a reduction 
in the ability of IL-10 to phosphorylate STAT3. While inhibition of IL-10 signaling 
was not observed with only 1 hour of LPS preincubation, we did not know if 
shorter exposures to LPS could cause IL-10R dysfunction. Studies by Ahmed 
and Ivashkiv demonstrate that preincubation of primary macrophages with LPS 
for 20 minutes inhibits IL-6 mediated STAT3 phosphorylation and that a 20 
minute exposure to IL-1 could block IL-10 mediated STAT3 phosphorylation (52). 
To evaluate short exposure time, PM were treated with LPS (1µg/ml) for 10-60 
minutes before the addition of 5 ng/ml of IL-10 for 30 minutes 	
(Fig. 1). The addition of IL-10 to untreated PM induced a 3-fold increase in the 
level of STAT3 phosphorylation. Prior incubation with LPS caused a moderate 
inhibition of STAT3 at 30 minuntes of LPS preincubation, which was not 
statistically significant. 
We next evaluated  whether longer exposures to LPS would alter IL-10 mediated 
STAT3 activation in PM. Preliminary experiments for this study failed to 
demonstrate any significant reduction in IL-10 mediated STAT3 phosphorylation 
in PMs pre-exposed to LPS for 1-10 hours (data not shown). Normal PM were 
pretreated with LPS (1µg/ml) for 12 and 34 hours hours before the addition of 
5 ng/ml of IL-10 for 30 minutes (Fig. 2). The addition of IL-10 to untreated PM 
induced an 8-fold increase in the level of STAT3 phosphorylation (lane2 vs. 
lane1) (p<0.0001). Also, there was a significant reduction in IL-10 mediated 
STAT3 phosphorylation at both 12 and 34 hours pretreatment with LPS compared 
to IL-10 treatment alone (p<0.0001). Delayed reduction in IL-10 mediated STAT3 
phosphorylation by LPS was not unique to PM from C57BL/6 mice, since it was 
also observed at 36 hours in PM from BALB/C, C3H/HeSnJ, and A/J mice (data 
not	shown).
Delayed Inhibition of IL-10 Signaling by LTA
PM were preexposed to the TLR2 ligand S. aureus	LTA	(1µg/ml) for 12 and 34 
hours before the addition of 5 ng/ml IL-10 for 30 minutes (Fig.3).  The addition 
of IL-10 to untreated PM induced an 8-fold increase in the level of STAT3 
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phosphorylation compared to untreated cells (p<0.0001). Also, there was a 
significant reduction in IL-10 mediated STAT3 phosphorylation at both 12 and 34 
hours pretreatment with LTA, compared to IL-10 only treated cells (p<0.0001). 
Delayed reduction in IL-10 mediated STAT3 phosphorylation by LTA was not 
unique to PM from C57BL/6 mice, since it was also observed at 36 hours in PM 
from BALB/C and C3H/HeSnJ mice (data not shown).
Delayed Inhibition of IL-10 Signaling by Poly I:C
PMs were pretreated with Poly (I:C) (20 µg/ml) for 12-36 hours before the 
addition of 5ng/ml of IL-10 for 30 minutes. The addition of IL-10 alone to 
untreated PM induced an 8-fold increase in the level of STAT3 phosphorylation 
(Fig. 4, lane2 vs. lane1) (p<0.05). Poly (I:C) alone for 12-36 hours did not 
significantly alter the level of STAT3 phosphorylation (Fig. 4, lanes 3,4,5). 
In contrast, there was a significant reduction in IL-10 mediated STAT3 
phosphorylation at 36 hours pretreatment with Poly (I:C), compared to IL-10 
treatment alone (p<0.05) (Fig. 4, lane 8). 24 hour Poly (I:C) pretreatment was 
also able to induce a fourfold decrease in STAT3 activation that approached 
significance (p=0.0617) (Fig. 4, lane 7).
Delayed Inhibition of IL-10 Signaling by Pam
3
CSK4
PMs were pretreated with Pam
3
CSK4 (200 ng/ml) for 12-36 hours before 
the addition of 5ng/ml of IL-10 for 30 minutes (Fig. 5). The addition of IL-10 
alone to untreated PM induced a significant increase in the level of STAT3 
phosphorylation compared to untreated cells (Fig 5, lane 2 vs. lane 1) 
(p<0.05). In contrast, Pam
3
CSK4 treatment alone did not significantly alter 
STAT3 phosphorylation compared to untreated PM (Fig. 5, lanes 3,4,5 vs. 
lane 1). However, there were significant reductions in IL-10 mediated STAT3 
phosphorylation at 12, 24, and 36 hours pretreatment with Pam
3
CSK4 compared 
to IL-10 treatment alone (p<0.05) (Fig. 5, lanes 6,7,8 vs. lane 2).
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Gene expression in peritoneal macrophages continually exposed to IL-10 
before TLR ligands
While the data from the previous experiments showed that TLR ligands could 
inhibit IL-10 signaling, it was important to determine if this inhibition had an effect 
on IL-10 induced genes. Consequently, the expression of the chemokine receptor 
gene, CCR5, was evaluated by RT-PCR in IL-10-exposed PMs, because this 
gene has been shown to be induced by IL-10, but not by TLR ligand binding 
(47,48). Previous studies in the laboratory have demonstrated that the TLR 
ligands LPS, LTA and CpG inhibit CCR5 gene expression in PMs pre-exposed to 
IL-10 (39). In this study, when PMs were exposed to IL-10 (5ng/ml), 	
CCR5 mRNA expression was induced and remained elevated for 26 hours. LPS 
(1µg/ml) was added 2 hours after the IL-10 treatments. The addition of LPS 2 
hours after IL-10 resulted in a 5-fold reduction in CCR5 mRNA expression (Fig. 
6). However, these results proved not to be statistically significant. These results 
indicate that the IL-10 mediated expression of the PM gene CCR5 may be 
altered when exposed to LPS. 
Similar experiments were conducted with Poly I:C (20 µg/ml) instead of LPS. 
Cells treated with IL-10 alone demonstrated a relatively low CCR5 activation 
(Fig.7, lane 2), which made it difficult to evaluate if Poly I:C could significantly 
reduce IL-10 mediated CCR5 expression in PM.
IL-10 immunosuppressive activity in ceramide-stimulated macrophages 
pre-exposed to TLR ligands
The ability of the TLR ligands Poly (I:C) and Pam
3
CSK4	to	block	the	IL-10	
mediated suppression of TNF-α production by C2-ceramide was also evaluated.  
C2-ceramide is a membrane permeable intracellular second messenger, 	
which mimics the activity of endogenously synthesized ceramide, a 
proinflammatory molecule produced by the cleavage of membrane sphingolipids. 
The addition of C2-ceramide to macrophages in vitro results in an increase of 
TNF-α production. Previous studies in the laboratory have demonstrated that 
LPS	inhibits	the	ability	of	IL-10	to	suppress	TNF-α production by C2-ceramide 
in PMs (39). In this study, the ability of Poly (I:C) and Pam
3
CSK4 to individually 
suppress	TNF-α production by C2-ceramide in PM was evaluated. Figure 8 
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demonstrates the influence of Poly I:C on the ability of IL-10 to suppress TNF-α	
production by C2-ceramide. Figure 9 demonstrates the influence of Pam
3
CSK4	
on	the	ability	of	IL-10	to	suppress	TNF-α production by C2-ceramide. The trends 
were similar for both studies. Only Fig. 9 will be described since the trends could 
be more easily observed.
In contrast to previous studies in our lab by Fernandez et al (39) which used 
LPS, the addition of Pam
3
CSK4 caused a 4-fold increase in TNF-α production 
(Fig. 9, lane 2 vs. lane1). As expected ceramide alone also induced TNF-α, but to 
relatively low level (Fig. 9, lane 3). The addition of IL-10 before ceramide inhibited 
the ability of ceramide to induce TNF-α (lane 5 vs. lane 3). The 
addition of ceramide to Pam
3
CSK4-pretreated cultures failed to induce TNF-α	
synthesis above the Pam
3
CSK4-induced level (lane 4 vs. lane 2). Consequently, 
the	ability	of	Pam
3
CSK4 to block the immunosuppressive effect of IL-10 could not 
be evaluated.
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Figure	1.	LPS does not show any early inhibition of IL-10 induced STAT3 
phosphorylation in PM. Normal PM were incubated with LPS (1µg/ml) for the 
indicated time periods before the addition of IL-10 (5ng/ml) for 30 minutes. Total 
protein extracts were obtained and 2-5 µg were analyzed by immunoblotting 
using anti-phospho-STAT3 or anti-STAT3 Abs. The average of three identical 
experiments +-S.E. is shown.
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Figure 2. LPS shows late inhibition of IL-10 induced STAT3 phosphorylation 
in PM. Normal PM were incubated with LPS (1µg/ml) for either 12 or 34 hours 
before the addition of IL-10 (5ng/ml) for 30 minutes. Total protein extracts were 
obtained and 2-5 µg were analyzed by immunoblotting using anti-phospho-
STAT3 or anti-STAT3 Abs. The average of two identical experiments +-S.E. is 
shown. ** indicates significantly different (p<0.0001) from cells treated with IL-10 
only. * indicates significantly different (p<0.0001) from untreated cells.  
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Figure 3. LTA shows late inhibition of IL-10 induced STAT3 phosphorylation 
in PM. Normal PM were incubated with LTA (1µg/ml) for either 12 or 34 hours 
before the addition of IL-10 (5ng/ml) for 30 minutes. Total protein extracts were 
obtained and 2-5 µg were analyzed by immunoblotting using anti-phospho-
STAT3 or anti-STAT3 Abs. The average of two identical experiments +-S.E. is 
shown. ** indicates significantly different (p<0.0001) from cells treated with IL-10 
only. * indicates significantly different (p<0.0001) from untreated cells.  
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Figure	4.	Poly (I:C) shows late inhibition of IL-10 induced STAT3 
phosphorylation in PM. Normal PM were incubated with or without Poly (I:C) 
(20 µg/ml) for either 12, 24 or 36 hours, before the addition of IL-10 (5ng/ml) for 
30 minutes. Total protein extracts were obtained and 2-5 µg were analyzed by 
immunoblotting using anti-phospho-STAT3 or anti-STAT3 Abs. The average of 
three identical experiments +-S.E. is shown. ** indicates significantly different 
(p<0.05) from cells treated with IL-10 only. * indicates significantly different 
(p<0.05) from untreated cells.  
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Fig. 5. Pam
3
CSK4 shows late inhibition of IL-10 induced STAT3 
phosphorylation in PM. Normal PMs were incubated with Pam
3
CSK4 (200 
ng/ml)  for either 12, 24 or 36 hours, before the addition of IL-10 (5ng/ml) for 
30 minutes. Total protein extracts were obtained and 2-5 µg were analyzed by 
immunoblotting using anti-phospho-STAT3 or anti-STAT3 Abs. The average of 
three identical experiments +-S.E. is shown. ** indicates significantly different 
(p<0.05) from cells treated with IL-10 only. * indicates significantly different 
(p<0.05) from untreated cells.  
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Fig. 6. CCR	5 gene expression in PM exposed to IL-10 before LPS.	PM	from	
normal mice were plated and pretreated with IL-10 (5ng/ml) for 26 hours. Two 
hours after the IL-10 stimulation, cells were treated with LPS or left untreated. 
Total RNA was extracted using TRIzol reagent. Complementary DNA was 
amplified using primers for murine CCR5. As a control, PCR was also performed 
for	β-actin. One of three identical experiments, all with similar results, is shown.
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Fig. 7. CCR	5 gene expression in PM exposed to IL-10 before Poly I:C.	PM	
from normal mice were plated and pretreated with IL-10 (5ng/ml) for 26 hours. 
Two hours after the IL-10 stimulation, cells were treated with Poly (I:C) or left 
untreated. Total RNA was extracted using TRIzol reagent. Complementary
DNA was amplified using primers for murine CCR5. As a control, PCR was 
also performed on for β-actin. Two identical experiments, both with similar 
results, is shown.
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Fig. 8. IL-10 immunosuppressive activity in ceramide-stimulated 
macrophages pre-exposed to Poly (I:C). Normal PM were treated with or 
without Poly (I:C) (20 µg/ml) for 24 hours. Poly (I:C) was then removed from 
the wells by rinsing and then cultured in serum-free medium for an additional 
2 hours in the presence or absence of IL-10 (5ng/ml). C2-ceramide was 
then added to the culture for an additional 4 hours. Medium was collected 
and assayed for TNF-α. The average of three identical experiments (each in 
duplicate) +- SE is shown.
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Fig. 9. IL-10 immunosuppressive activity in ceramide-stimulated 
macrophages pre-exposed to Pam
3
CSK4. Normal PM were treated with or 
without	Pam
3
CSK4 (200 ng/ml) for 24 hours. Pam
3
CSK4 was then removed 
from the wells by rinsing and then cultured in serum-free medium for an 
additional 2 hours in the presence or absence of IL-10 (5ng/ml). C2-ceramide 
was then added to the culture for an additional 4 hours. Medium was collected 
and assayed for TNF-α. The average of three identical experiments (each in 
duplicate) +- SE is shown.
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Discussion
Results from the western blot analyses in this study indicate that the activation of 
STAT3 by IL-10 was inhibited by prior exposure of PM to TLR ligands that bind 
to TLR2, TLR3, or TLR4. LPS, LTA, Poly I:C, and Pam
3
CSK4, all demonstrated 
a delayed inhibition of activation of STAT3 by IL-10. LPS and LTA demonstrated 
significant inhibition of IL-10 mediated STAT3 activation at both 12 and 34 
hours.	Pam
3
CSK4 demonstrated significant inhibition of IL-10 mediated STAT3 
activation at 12, 24, and 36 hours, while Poly I:C showed a significant inhibition of 
the same only at 36 hours. Previous studies in the laboratory have observed that 
PM and AM respond identically to TLR ligands. From a single mouse PM can be 
isolated in much larger quantities than AM. Therefore, PM were chosen for this 
study on TLR-mediated IL-10R dysfunction, although the peritoneal fluid contains 
a hundredfold lower concentration of IL-10 compared to bronchioalveolar fluid. 
PM are not normally exposed to environmental particulates or microorganisms 
as frequently as AM. Thus, the physiological significance of IL-10R dysfunction in 
PM is unclear (39). 
In the normal lung, AM in the bronchioalveolar fluid are continually exposed 
to IL-10. Our previous studies have also been able to demonstrate elevated 
expression of CCR1 and CCR5 mRNA in normal PM that were exposed to IL-10 
for 10 hours. Subsequent addition of LPS two hours later inhibited expression 
of both CCR1 and CCR5 mRNA (39). Similarly, CCR5 gene expression 
experiments in this study demonstrated that LPS treatment 2 hours after a 24 
hour IL-10 treatment down-regulated CCR5 mRNA expression in PM. However, 
this down-regulation only approached statistical significance (P=0.06). In similar 
experiments in which Poly I:C was added instead of LPS, there was no down-
regulation in CCR5 expression. It would be interesting to examine if Pam
3
CSK4	
is capable of altering IL-10 induced CCR5 gene expression since Pam
3
CSK4	
only signals via the MyD88 pathway. IL-10 also induces the expression of the 
CCR1, but inhibits the expression of CCR7 in macrophages. Thus, the ability of 
both Poly (I:C) and Pam
3
CSK4 to alter CCR1 and CCR7 expression in PM would 
also	be	worth	examining.	
We performed additional experiments in which we evaluated the ability of Poly (I:
35
C) and Pam
3
CSK4	to	alter	the	ability	of	IL-10	to	inhibit	TNF-α production by C2-
ceramide. In these experiments, both Poly (I:C) and Pam
3
CSK4 produced high 
background levels of TNF-α, which made it difficult to determine if there was any 
significant influence of any of the ligands on IL-10 mediated immunosuppression. 
Alexopoulou	et al (54) have reported that Poly (I:C) can induce activation of 
NF-κB, and Pam
3
CSK4 is also known to induce NF-κB through the MyD88 
dependent signaling pathway (42); which may explain the high background levels 
of	TNF-α observed in the experiments of this study. Also similar experiments 
conducted by Fernandez et al required several preliminary studies to optimize 
background levels of TNF-α production. The immunoblot experiments in Figures 
4 and 5 indicate that both Poly (I:C) and Pam
3
CSK4 are capable of reducing 
IL-10 receptor function in PM. This suggests that IL-10R dysfunction in PM 
could occur via both the IRF-3 dependent and MyD88 dependent TLR signaling 
pathways.	Pam
3
CSK4 mediates signaling through TLR2, which activates the 
MyD88 dependent pathway, inducing IL-6, TNF-α, and IL-12 via NF-κB.	Using	
MyD88-/- mice, our lab has also demonstrated that inhibition of IL-10 mediated 
STAT3 activation by TLR ligands in PM is dependent on MyD88 (39). 
The delayed inhibition observed in this study with all the TLR ligands indicates 
the possibility that inducible factors like cytokines may be involved in the 
observed IL-10R dysfunction. Previous studies in the laboratory have observed 
that	TNF-α induces partial resistance to IL-10 in normal PM (38). Neutralizing 
antibodies against TNF-α could be used in future studies to evaluate the possible 
role	of	TNF-α in the IL-10R dysfunction observed in this study. Poly (I:C) signals 
through TLR3, which can mediate production of IFN-α and IFN-β.	LPS	signals	
through TLR4, which induces IFN- β, but not IFN-α production (42). This makes 
IFN- β a likely candidate in mediating the observed IL-10R dysfunction in PM. 
Neutralizing antibodies against IFN- β could also be used in future studies to 
evaluate the possible role of this cytokine in the IL-10R dysfunction observed in 
this study. It has been demonstrated in macrophages that IFN-γ redirects IL-10 
signaling from the activation of STAT3 to STAT1 (55). STAT3 and STAT1 oppose 
each other in the regulation of several important cellular functions, including 
proliferation and inflammation (49). There is evidence which shows that individual 
cytokines can activate STATs which oppose each other’s function (50). It has 
also been observed that IFN-γ	sensitizes	macrophages	such	that	IL-10	signaling	
can be nearly completely blocked after FcγR	ligation	by	immune	complexes	
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(29). Pretreatment of mouse leukemia M1 cell line with IFN-γ	has	been	shown	
to result in SOCS1 induction and a reduction in STAT3 activation by IL-10 (32). 
Other reports show that IL-10 signaling can be relatively resistant to inhibition by 
SOCS proteins, dependent on cell type, and suggest that SOCS3 may not be 
involved in the regulation of IL-10R signaling (35, 36). If expression of SOCS1 or 
SOCS3 is involved in IL-10R hyporesponsiveness, then overexpression of either 
of these proteins should also lead to the hyporesponsive state independently of 
TLR signaling. In future studies macrophage cell lines could be stably transfected 
with expression plasmids for murine SOCS1 and SOCS3. The ability of IL-10 to 
induce STAT3 phosphorylation in the tranfected and untransfected cell lines could 
then be compared by incubating the cells in IL-10. If either of the SOCS proteins 
are involved in IL-10R hyporesponsiveness, overexpression of the specific SOCS 
would inhibit IL-10 signaling, whereas the empty plasmid would have no effect. If 
overexpression SOCS reduces IL-10 signaling, flow cytometry could be used to 
verify that the expression of IL-10 receptors is unaltered.
Studies by Ahmed and Ivashkiv (52) demonstrate that preincubation of 
primary macrophages with LPS for 20 minutes inhibits IL-6 mediated STAT3 
phosphorylation, and that 20 minutes of exposure to IL-1 could block IL-10 
mediated STAT3 phosphorylation (52). In our study, pretreatment of PM with LPS 
did not demonstrate any early or rapid inhibition of STAT3 activation by IL-10. 
However, preliminary experiments in this study have revealed that   preincubation 
of PM with LPS for both 10 and 20 minutes was able to inhibit IL-6 induced 
STAT3 phosphorylation, at P<0.005 and P<0.05, respectively (data not shown). 
Future studies could evaluate the ability of Poly I:C to cause any early or rapid 
inhibition of IL-10R function, since Poly I:C is known to induce activation of the 
p38 mitogen-activated protein kinase (51). p38 has been shown to inhibit IL-6 
signaling upstream of STAT3 activation (52). 
In conclusion, this study demonstrates that Poly I:C, and Pam
3
CSK4	are	both	
capable of mediating a delayed inhibition of IL-10R function, at least at the 
level of STAT3 activation. The mechanism underlying this observation is yet to 	
be resolved. 
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